Elanco Animal Health Incorporated Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Elanco Animal Health Incorporated (ELAN) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $223.00 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-02-24
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $223.00M.
- 2024-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2025-12-31 | $223.00M 10-K · filed 2026-02-24 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |